Inclusion-Body Myositis Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis (sIBM)Intervention: Drug: BYM338 (Bimagrumab)Sponsor: Novartis PharmaceuticalsRecruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2014 Category: Research Source Type: clinical trials
Natalizumab in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis (IBM)Intervention: Drug: NatalizumabSponsor: Phoenix Neurological Associates, LTDRecruiting - verified June 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 31, 2013 Category: Research Source Type: clinical trials
